DPP4 and hydrops fetalis: Conversely, the DPP-4 inhibitor, saxagliptin, is not recommended in diabetic patients with HF, since it was observed to increase HF hospitalization; no difference over placebo for HF events was found with alogliptin, sitagliptin, and linagliptin (24).